New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 13, 2012
07:35 EDTSNTASynta Pharmaceuticals announces $60M registered direct common stock offering
Synta Pharmaceuticals has entered into common stock purchase agreements with members of its Board of Directors and various institutional investors for the sale of 7,000,000 shares of its common stock in an issuer directed, registered direct offering. Shares were priced at $8.60, the consolidated closing bid price as of December 12 for gross proceeds of approximately $60M. No underwriter or placement agent was used in this transaction. The offering is expected to close on or about December 18, subject to satisfaction of customary closing conditions. Net proceeds from the offering will be used to fund Synta's operations, including, research and development, clinical trials, manufacturing, intellectual property protection and enforcement, and working capital, and for other general corporate purposes.
News For SNTA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 9, 2015
17:53 EDTSNTASynta Pharmaceuticals management to meet with Roth Capital
Subscribe for More Information
October 8, 2015
07:37 EDTSNTASynta Pharmaceuticals announces formation of expert oncology panel
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use